On the Alert for Cytokine Storm: Immunopathology in <scp>COVID</scp>‐19

Lauren A. Henderson(Boston Children's Hospital), Scott Canna(University of Pittsburgh), Grant S. Schulert(Cincinnati Children's Hospital Medical Center), Stefano Volpi(Istituto Giannina Gaslini), Pui Y. Lee(Boston Children's Hospital), Kate F. Kernan(University of Pittsburgh), Roberto Caricchio(Temple University Hospital), Shawn A. Mahmud(University of Minnesota Medical Center), Melissa M. Hazen(Boston Children's Hospital), Olha Halyabar(Boston Children's Hospital), Kacie J. Hoyt(Boston Children's Hospital), Joseph Han(Icahn School of Medicine at Mount Sinai), Alexei A. Grom(Cincinnati Children's Hospital Medical Center), Marco Gattorno(Istituto Giannina Gaslini), Angelo Ravelli(Istituto Giannina Gaslini), Fabrizio De Benedetti(Bambino Gesù Children's Hospital), Edward M. Behrens(Children's Hospital of Philadelphia), Randy Q. Cron(Children's of Alabama), Peter A. Nigrović(Brigham and Women's Hospital)
Arthritis & Rheumatology
April 15, 2020
Cited by 655Open Access
Full Text

Abstract

Poor outcomes in COVID-19 correlate with clinical and laboratory features of cytokine storm syndrome. Broad screening for cytokine storm and early, targeted antiinflammatory therapy may prevent immunopathology and could help conserve limited health care resources. While studies are ongoing, extrapolating from clinical experience in cytokine storm syndromes may benefit the multidisciplinary teams caring for patients with severe COVID-19.


Related Papers

No related papers found

Powered by citation graph analysis